Author

Jeffrey Martini

Observed names: J. Martini, Jeff Martini

Observed institution: Cleveland Clinic

ORCID: 0000-0002-2230-2670

Observed ORCID: 0000-0002-2230-2670

OpenAlex ID: A5076574033

Sirolimus in the Treatment of Microcystic Lymphatic Malformations: A Systematic Review

2022 · Joyce M.C. Teng, Adrienne Hammill, et al. · Lymphatic Research and Biology · 20

Annual prevalence estimation of lymphatic malformation with a cutaneous component: observational study of a national representative sample of physicians

2022 · Jack Ray Gallagher, J. Martini, et al. · Orphanet Journal of Rare Diseases · 9

Sirolimus for Venous Malformations: A Systematic Review of Efficacy and Safety

2025 · Joyce Teng, Jeff Martini, et al. · Lymphatic Research and Biology · 5

Phase 2 study of the safety and efficacy of QTORIN rapamycin in the treatment of microcystic lymphatic malformations

2024 · James Treat, Jeffrey Martini, et al. · Journal of Vascular Anomalies · 2

Currently managed US prevalence of cutaneous venous malformations (cVMs): a nationally representative, retrospective, real-world, subject-blinded, physician-observational probability study

2025 · Jack Ray Gallagher, Susan Carroll, et al. · Orphanet Journal of Rare Diseases · 1

76929 The experience of living with porokeratosis, a serious rare disease: a patient and caregiver perspective

2026 · Lihi Atzmony Maoz, Jeffrey Martini, et al. · Journal of the American Academy of Dermatology

76954 QTORIN Rapamycin: Advancing Topical Formulation Science for Rare Dermatologic Conditions

2026 · Jeffrey Martini, David Osborne, et al. · Journal of the American Academy of Dermatology

Assessing Clinical Meaningfulness to Patients Through the TSQM: Results from a Phase 2 Trial with QTORIN TM Rapamycin

2026 · Maria Gnarra Buethe, Joyce Teng, et al. · Journal of Investigative Dermatology

120: SELVA: A Phase 3 Study with a Fit-For-Purpose Primary Endpoint Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

2025 · Joyce Teng, James Treat, et al. · Journal of Investigative Dermatology

119: QTORIN rapamycin 3.9% anhydrous gel: A Novel, Dermal-Targeted Topical mTOR inhibitor in Phase 3 for treatment of Microcystic Lymphatic Malformations

2025 · Jeffrey Martini, Braham Shroot, et al. · Journal of Investigative Dermatology

Works count: 10

Citation count: 37

H-index: 3

I10-index: 1